Drug safety assessment in clinical trials: methodological challenges and opportunities
Tóm tắt
Từ khóa
Tài liệu tham khảo
Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials. September 21, 2010, Springer, New York, 4
Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events with Varenicline- A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CMAJ. 2011, 183: 1359-1366. 10.1503/cmaj.110218.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010, 121: 221-229. 10.1161/CIRCULATIONAHA.109.869008.
Harrison-Woolrych M, Maggo S, Tan M, Savage R, Ashton J: Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf. 2012, 35: 33-43. 10.2165/11597690-000000000-00000.
Singh S, Loke YK, Enright P, Furberg CD: Mortality associated with tiotropium Respimat® in patients with chronic obstructive pulmonary disease − A systematic review and meta-analysis of randomized controlled trials. BMJ. 2011, 342: d3215-10.1136/bmj.d3215.
Singh S, Loke YK, Furberg CD: Inhaled anticholinergics and the risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA. 2008, 300: 1439-1450. 10.1001/jama.300.12.1439.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007, 356: 2457-2471. 10.1056/NEJMoa072761.
Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone − A systematic review and meta-analysis. JAMA. 2007, 298: 1189-1195. 10.1001/jama.298.10.1189.
Loke YK, Kwok CS, Singh S: Comparative cardiovascular effects of thiazolidinediones: A systematic review and meta-analysis of observational studies. BMJ. 2011, 342: d1309-10.1136/bmj.d1309.
Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: Systematic review. CMAJ. 2009, 180: 32-39. 10.1503/cmaj.080486.
Hammad TA, Pinheiro SP, Neyarapally GA: Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin Trials. 2011, 8: 559-570. 10.1177/1740774511419165.
Scudellari M: Pooled studies can raise misleading alarm bells, regulators say. Nat Med. 2010, 16: 1051-10.1038/nm1010-1051.
Lane PW: Meta-analysis of incidence of rare events. Stat Methods Med Res. 2012 Jan 4, Epub ahead of print
Bradburn MJ, Deeks JJ, Berlin JA: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007, 26: 53-77. 10.1002/sim.2528.
Sweeting MJ, Sutton AJ, Lambert PC: What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004, 23: 1351-1375. 10.1002/sim.1761.
Food and Drug Administration Amendments Act of 2007. Sep 27. 2007, http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf Accessed August 17, 2012
Moore TJ, Singh S, Furberg CD: The FDA and new safety warnings. Arch Intern Med. 2012, 172: 78-80. 10.1001/archinternmed.2011.618.
Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S: Suicidal behavior and depression in smoking cessation treatments. PLoS One. 2011, 6: e27016-10.1371/journal.pone.0027016.
Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G: Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009, 339: b2880-10.1136/bmj.b2880.
Institute of Medicine Report: Evaluation of biomarkers and surrogate endpoints in chronic disease. May 12, 2010, Washington:DCNational Academies Press, ISBN-10: 0-309-15129-5. ISBN 10: 0-309-15129-5
US Department of Health and Human Services, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry. Diabetes Mellitus. Evaluating Cardiovascular Risk in New Antidiabetic therapies to treat Type 2 Diabetes. December 2008, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed January 30, 2012
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998, 352: 854-865.
Duckworth W, Abraira C, Moritz T: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009, 360: 129-139. 10.1056/NEJMoa0808431.
The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008, 358: 2545-2559.
The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008, 358: 2560-2572.
Singh S, Amin AV, Loke YK: Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009, 169 (3): 219-229. 10.1001/archinternmed.2008.550.
Singh S, Loke YK: Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010, 16 (2): 118-122. 10.1097/MCP.0b013e328334c085.
Singh S, Loke YK, Furberg CD: Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. Thorax. 2011, 66: 383-388. 10.1136/thx.2010.152777.
Kwok CS, Loke YK: Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf. 2012, 35: 127-139. 10.2165/11594900-000000000-00000.
Singh S: Loke YK, Enright P: Furberg CD. Thorax: 2012 Jul 4, Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications, [Epub ahead of print]
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008, 359: 1543-1554. 10.1056/NEJMoa0805800.
Derry S, Loke YK: Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000, 321: 1183-1187. 10.1136/bmj.321.7270.1183.
Loke YK, Derry S: Aronson JK: A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol. 2004, 57: 616-621. 10.1111/j.0306-5251.2003.02055.x.
Loke YK, Golder S, Vanderbroucke JP: Comprehensive evaluation of adverse effects of drugs: importance of appropriate study selection and data source. Therapeutic Advances in Drug Safety. 2011, 2: 59-68. 10.1177/2042098611401129.
Golder S, Loke YK, Bland M: Meta-analyses of adverse effects data derived from randomized controlled trials as compared to observational studies: methodological overview. PLoS Med. 2011, 8: e1001026-10.1371/journal.pmed.1001026.
Woodcock J, Behrman RE, Dal Pan GJ: Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011, 62: 1-10. 10.1146/annurev-med-060309-164311.
Home PD, Pocock SJ, Beck-Nielsen H: RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009, 373: 2125-2135. 10.1016/S0140-6736(09)60953-3.
Treadwell JR, Uhl S, Tipton K, Shamliyan T, Viswanathan M, Berkman ND, Sun X, Coleman CI, Elshaug AG, Singh S, Wang SY, Ramakrishnan R: Assessing equivalence and noninferiority. J Clin Epidemiol. 2012 Jun 23, Epub ahead of print
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK: PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 2005, 366: 1279-1289. 10.1016/S0140-6736(05)67528-9.
Hillaire-Buys D, Faillie JL, Montastruc JL: Pioglitazone and bladder cancer. Lancet. 2011, 378: 1543-1544.
Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M: Do we need to adjudicate major clinical events?. Clin Trials. 2008, 5: 56-60. 10.1177/1740774507087972.
Vedula SS, Bero L, Scherer RW, Dickersin K: Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009, 361: 1963-1971. 10.1056/NEJMsa0906126.
Wang AT, McCoy CP, Murad MH, Montori VM: Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010, 340: c1344-10.1136/bmj.c1344.
Mills EJ, Wu P, Chong G, Ghement I, Singh S: Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. Q J Med. 2011, 104: 109-124. 10.1093/qjmed/hcq165.
Thorlund K: What is the power to demonstrate that varenicline use for tobacco cessation is not associated with an increase in cardiovascular serious adverse events?. http://www.bmj.com/content/344/bmj.e2856/rr/587196 Accessed July 17, 2012
Sherman RB, Woodcock J, Norden J, Grandinetti C, Temple RJ: New FDA regulation to improve safety reporting in clinical trials. N Engl J Med. 2011, 365: 3-5. 10.1056/NEJMp1103464.
Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC: The ClinicalTrials.gov results database–update and key issues. N Engl J Med. 2011, 364: 852-860. 10.1056/NEJMsa1012065.
Li T, Puhan MA, Vedula SS, Singh S: Network meta-analysis-highly attractive but more methodological research is needed. BMC Medicine. 2011, 9: 79-10.1186/1741-7015-9-79.
European Medicines Agency: Benefit Risk Methodology. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp%26mid=WC0b01ac0580223ed6 Accessed July 17, 2012